In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
ID: 357009Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357009

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-140.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for in-depth phenotyping and research using knockout mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Clinical Trial Not Allowed grant mechanism. This initiative aims to encourage applications that leverage the International Mouse Phenotyping Consortium (IMPC) resources to better understand genetic functions related to congenital diseases and structural defects, particularly those affecting embryonic development and fertility. The program is part of a broader effort to catalog mammalian gene function, with an award ceiling of $499,999 per year for projects lasting up to five years. Interested applicants must submit their proposals by January 7, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-140-Full-Announcement.html
    PAR-25-140.html
    The Department of Health and Human Services is issuing a funding opportunity through the National Institutes of Health (NIH) aimed at in-depth research and phenotyping of embryonic lethal and subviable knockout mouse strains produced by the International Mouse Phenotyping Consortium (IMPC). The initiative, which falls under the R01 Research Project Grant, encourages applications that focus on understanding genetic functions related to congenital diseases and structural defects, including fertility issues linked to embryonic development. Key dates for application submissions range from May 5, 2025, to June 5, 2025, with a project duration of up to five years and budgets of up to $499,999 annually. Interested applicants are urged to adhere to specific NIH guidelines, including a resource-sharing plan for generated data and biospecimens. The existing program, KOMP2, expects an increase in available mouse strains and aims to enhance knowledge critical to gene function in human health. Eligible applicants include various higher education institutions and nonprofit organizations, with an emphasis on inclusion from diverse backgrounds. This opportunity reflects NIH's commitment to advancing biomedical research and improving health outcomes through innovative genetic studies.
    Similar Opportunities
    In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for in-depth phenotyping and research using knockout (KO) mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Research Project Grant mechanism (Funding Opportunity Announcement PAR-23-074). This initiative encourages applications to perform detailed phenotyping on specific KO mouse cohorts or to utilize these strains in hypothesis-driven research related to congenital diseases and fertility issues, contributing to the mission of the International Mouse Phenotyping Consortium (IMPC) to catalog mammalian gene functions. The funding amount can reach up to $499,999 per year for a duration of five years, with applications due by January 7, 2026. Interested applicants can find more information and guidance on the submission process at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Informatics, Coordination and Service Center (ICSC) for the Mutant Mouse Resource and Research Centers (MMRRC) consortium through the funding opportunity RFA-OD-25-012. The ICSC is tasked with providing essential informatics and coordinating services, including the development and maintenance of data management systems, operation of a public website and customer service center, and facilitation of interactions among biomedical researchers. This initiative is particularly focused on integrating New Approach Methodologies (NAMs) with traditional animal research to enhance predictive models of human diseases. The estimated total program funding is $878,000, with a maximum annual budget cap of $650,000 in direct costs, and applications are due by May 2, 2026. For further inquiries, interested applicants can contact Oleg Mirochnitchenko, Ph.D., at ORIPDCM@mail.nih.gov.
    Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Informatics, Coordination and Service Center (ICSC) within the Mutant Mouse Resource and Research Centers (MMRRC) consortium, aimed at enhancing biomedical research through improved informatics services. The initiative seeks to support projects that develop and assist resources related to animal and biological materials, focusing on the integration of new approach methodologies (NAMs) alongside traditional animal-based research. This funding opportunity, utilizing the U42 activity code, is expected to provide a total of $878,000, with one award anticipated, and applications will be accepted starting in Summer 2025, following the NOFO publication in Spring 2025. For further inquiries, interested applicants can contact Dr. Oleg Mirochnitchenko at oleg.mirochnitchenko@nih.gov or by phone at 301-425-0479.
    Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the screening and functional validation of genomic variants associated with human congenital anomalies through the R01 Clinical Trial Not Allowed grant. This initiative aims to leverage advancements in genomic technologies to identify and validate genetic variants linked to congenital defects, intellectual developmental disabilities, and inborn errors of metabolism, thereby bridging the gap between genetic identification and functional impact on health. Eligible applicants include a wide range of institutions such as universities, nonprofits, and tribal governments, with a maximum budget of $499,999 per project year and a project duration of up to five years. Interested parties should submit their applications by January 7, 2028, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html for further details.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the establishment of Animal and Biological Material Resource Centers under the Notice of Funding Opportunity (NOFO) RFA-OD-25-011. This initiative aims to support the creation, preservation, and distribution of high-quality laboratory animals and biological materials, while also integrating new approach methodologies (NAMs) that complement traditional animal-based research. The program is crucial for enhancing research infrastructure and ensuring the availability of resources that facilitate scientific rigor and reproducibility in biomedical research. A total funding amount of $1.3 million is anticipated to support at least two awards annually from FY 2023-2025, with applications due by January 9, 2029. Interested applicants can reach out to the Office of Research Infrastructure Programs at ORIPDCM@mail.nih.gov for further information.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.